Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
7-8
pubmed:dateCreated
2001-2-2
pubmed:abstractText
We have demonstrated earlier the usefulness of recombinant porcine parvovirus (PPV) virus-like particles (VLPs) as an efficient recombinant vaccine for PPV. Here, we have demonstrated that preparations of PPV VLPs could be contaminated by recombinant baculoviruses. Since these baculoviruses can be a problem for the registration and safety requirements of the recombinant vaccine, we have tested different baculovirus inactivation strategies, studying simultaneously the integrity and immunogenicity of the VLPs. These methods were pasteurization, treatment with detergents and alkylation with binary ethylenimine (BEI). The structural and functional integrity of the PPV VLPs after the inactivation treatments were analyzed by electron microscopy, hemagglutination, double antibody sandwich (DAS)-ELISA and immunogenicity studies. Binary ethylenimine and Triton X-100 inactivated particles maintained all the original structural and antigenic properties. In addition, PPV VLPs were subjected to size-exclusion chromatography to analyze the presence of VP2 monomers or any other contaminant. The resulting highly purified material was used as the standard of reference to quantify PPV VLPs in order to determine the dose of vaccine by DAS-ELISA. After immunization experiments in guinea pigs, the antibody titers obtained with all the inactivation procedures were very similar. Triton X-100 treatment was selected for further testing in animals because of the speed, simplicity and safety of the overall procedure.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
0264-410X
pubmed:author
pubmed:issnType
Print
pubmed:day
22
pubmed:volume
19
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
726-34
pubmed:dateRevised
2008-11-21
pubmed:meshHeading
pubmed-meshheading:11115693-Animals, pubmed-meshheading:11115693-Antiviral Agents, pubmed-meshheading:11115693-Aziridines, pubmed-meshheading:11115693-Baculoviridae, pubmed-meshheading:11115693-Base Sequence, pubmed-meshheading:11115693-Cell Line, pubmed-meshheading:11115693-Chromatography, Gel, pubmed-meshheading:11115693-DNA Primers, pubmed-meshheading:11115693-Detergents, pubmed-meshheading:11115693-Enzyme-Linked Immunosorbent Assay, pubmed-meshheading:11115693-Guinea Pigs, pubmed-meshheading:11115693-Hot Temperature, pubmed-meshheading:11115693-Microscopy, Electron, pubmed-meshheading:11115693-Parvoviridae Infections, pubmed-meshheading:11115693-Parvovirus, pubmed-meshheading:11115693-Spodoptera, pubmed-meshheading:11115693-Swine, pubmed-meshheading:11115693-Swine Diseases, pubmed-meshheading:11115693-Vaccines, Synthetic, pubmed-meshheading:11115693-Viral Vaccines
pubmed:year
2000
pubmed:articleTitle
Effect of different baculovirus inactivation procedures on the integrity and immunogenicity of porcine parvovirus-like particles.
pubmed:affiliation
Inmunología y Genetica Apl. S.A. (INGENASA), Hnos. García Noblejas 41, 4 degrees, 28037, Madrid, Spain.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't